https://www.pharmaradar360.com/article/b8eee50705b58146Pharma Surgeen2026-05-13T10:43:35.000ZMedicines Pipeline datahttps://www.pharmaradar360.com/article/36969b1503ec5e71Pharma Surgeen2026-05-13T10:09:38.000ZMedical devices: ask for a regulatory advice meeting from the MHRAhttps://www.pharmaradar360.com/article/1b3628b5023e8bdcPharma Surgeen2026-05-13T10:02:47.000ZZymeworks Announces Participation in Upcoming Investor Conferenceshttps://www.pharmaradar360.com/article/f264068852a10666Pharma Surgeen2026-05-13T10:00:55.000ZLa AEMPS informa de un riesgo en los paquetes de baterías Zinc-Aire M de los procesadores de sonido de Advanced Bionicshttps://www.pharmaradar360.com/article/159381fc198d2e65Pharma Surgeen2026-05-13T09:19:52.000ZDecision: Orphan registered medicinal productshttps://www.pharmaradar360.com/article/9cdddbeae09f9af5Pharma Surgeen2026-05-13T08:59:51.000ZLa AEMPS informa de la retirada de dos lotes del medicamento veterinario Febrinol SP 650mg/g, polvo para administración en agua de bebida para cerdos de engorde y pollos de engordehttps://www.pharmaradar360.com/article/147e435381dd79f2Pharma Surgeen2026-05-13T08:56:53.000ZFEBRINOL S.P. 650 MG/G POLVO PARA ADMINISTRACION EN AGUA DE BEBIDA PARA CERDOS DE ENGORDE Y POLLOS DE ENGORDE (Nº 1647 ESP)https://www.pharmaradar360.com/article/939329480d3c6ee5Pharma Surgeen2026-05-13T06:05:49.000ZNotice of Preliminary Results and Investor Presentationhttps://www.pharmaradar360.com/article/262427612cf95399Pharma Surgeen2026-05-13T06:04:22.000ZIssue of Equity and Total Voting Rightshttps://www.pharmaradar360.com/article/52b448dbb122d2e3Pharma Surgeen2026-05-13T04:00:10.000ZSumitomo Pharma Announces Personnel Changeshttps://www.pharmaradar360.com/article/f27bea3e1c10c7bePharma Surgeen2026-05-13T03:00:00.000Z[SHINSA]Seven English translations of notifications and administrative notices related to pediatric drug development, including the partial revision of “Planning of the Pediatric Drug Development Program during Development of Drugs for Adults”https://www.pharmaradar360.com/article/b106242c61060257Pharma Surgeen2026-05-13T02:00:00.000ZAgenda for June 2026 Rheumatology Advisory Committee meetinghttps://www.pharmaradar360.com/article/acea09811c1bbb0fPharma Surgeen2026-05-13T00:00:00.000Znatco records %e2%82%b9705 4 crore consolidated revenue and %e2%82%b9151 3 crore of profit after tax for q3fy26https://www.pharmaradar360.com/article/b862699f76a57d71Pharma Surgeen2026-05-13T00:00:00.000Znatco records %e2%82%b91463 crore consolidated revenue and %e2%82%b9517 9 crore of profit after tax for q2fy26https://www.pharmaradar360.com/article/247f212ed92db305Pharma Surgeen2026-05-13T00:00:00.000Znatco receives tentative approval for erdafitinib tablets generic of balversa from the united states food and drug administration u s fdahttps://www.pharmaradar360.com/article/a8ca355dfb49784cPharma Surgeen2026-05-13T00:00:00.000Znatco receives approval from central drug standard control organisation cdsco for semaglutide in indiahttps://www.pharmaradar360.com/article/345d7798f5e52353Pharma Surgeen2026-05-13T00:00:00.000Znatco pharma limited api unit in chennai receives establishment inspection report eir from u s fdahttps://www.pharmaradar360.com/article/551bfac1f1fa9b6bPharma Surgeen2026-05-13T00:00:00.000Znatco pharma launches semaglutide generic injection multi dose vials in india at the most affordable price starting from mrp inr 1290https://www.pharmaradar360.com/article/3101bfd6b6c91725Pharma Surgeen2026-05-13T00:00:00.000Znatco announces launch of pomalidomide capsules generic of pomalyst in the u s markethttps://www.pharmaradar360.com/article/a4c2ddb325c4a520Pharma Surgeen2026-05-13T00:00:00.000Znatco announces launch of its everolimus tablets 1 mg generic of zortresshttps://www.pharmaradar360.com/article/b58145900167d185Pharma Surgeen2026-05-13T00:00:00.000Zlegal update regarding risdiplamhttps://www.pharmaradar360.com/article/19099f18d12f2675Pharma Surgeen2026-05-13T00:00:00.000Zintimation under regulation 30 of sebi listing obligations and disclosure requirements regulations 2015 2https://www.pharmaradar360.com/article/c77249b50b0f1b23Pharma Surgeen2026-05-13T00:00:00.000Zdisclosure under regulation 30 of the sebi listing obligations and disclosure requirements regulations 2015https://www.pharmaradar360.com/article/8614f048bcf627b8Pharma Surgeen2026-05-13T00:00:00.000Zadcock ingram completes delisting from jse natco pharma acquires 35 75 stakehttps://www.pharmaradar360.com/article/360b868134c5d681Pharma Surgeen2026-05-13T00:00:00.000Z6203https://www.pharmaradar360.com/article/33786c4d6f602bb5Pharma Surgeen2026-05-13T00:00:00.000ZHome pagehttps://www.pharmaradar360.com/article/51929ded1ac736a4Pharma Surgeen2026-05-13T00:00:00.000ZBausch Health to Participate in RBC Capital Markets 2026 Global Healthcare Conferencehttps://www.pharmaradar360.com/article/f674c8a680f43d0dPharma Surgeen2026-05-12T22:01:00.000ZLilly's Foundayo and lower-dose Zepbound helped people maintain weight loss after switching from higher doses of injectable incretin therapy in two late-phase trialshttps://www.pharmaradar360.com/article/30805e21a8abe0e8Pharma Surgeen2026-05-12T20:05:00.000ZRelmada Therapeutics Reports First Quarter 2026 Financial Results and Provides Business Updatehttps://www.pharmaradar360.com/article/d1a9d595fc8e69bdPharma Surgeen2026-05-12T16:29:40.000ZBorderline products: how to tell if your product is a medicinehttps://www.pharmaradar360.com/article/45b0047e3cbc03fePharma Surgeen2026-05-12T16:15:28.000ZRECORDATI: STRONG MOMENTUM OF THE GROUP CONTINUES INTO THE FIRST QUARTER OF 2026 NET REVENUE +4.9%, EBITDA +5.0%, ADJUSTED NET INCOME +7.2%https://www.pharmaradar360.com/article/bff97773f082ca6fPharma Surgeen2026-05-12T16:00:00.000ZChina med-tech raises: Star Sports’ $105M IPO; Cofoe nabs $133Mhttps://www.pharmaradar360.com/article/8f2c4252981cba3dPharma Surgeen2026-05-12T16:00:00.000ZMultiple appearances on Priority Watch List leading to action?https://www.pharmaradar360.com/article/f9cc067e14e74d5ePharma Surgeen2026-05-12T16:00:00.000ZMakary out at the FDAhttps://www.pharmaradar360.com/article/c4825b96be0529baPharma Surgeen2026-05-12T16:00:00.000ZMetis Techbio, Impact Tx cleared for Hong Kong IPOshttps://www.pharmaradar360.com/article/5646ec14b0d7dc8bPharma Surgeen2026-05-12T16:00:00.000ZIn honor of its 150th anniversary, Eli Lilly and Company commits to support community organizations aiming to provide 500,000 meals and cold storage for 150 food pantrieshttps://www.pharmaradar360.com/article/d4045d47c3d8316dPharma Surgeen2026-05-12T14:15:24.000ZField Safety Notices: 27 April to 1 May 2026https://www.pharmaradar360.com/article/3f52f51baa622b37Pharma Surgeen2026-05-12T14:14:00.000ZIZERVAY® (avacincaptad pegol intravitreal solution) Demonstrated Increased Probability of Maintaining Driving Eligibility in Geographic Atrophy Patientshttps://www.pharmaradar360.com/article/611388032890ce33Pharma Surgeen2026-05-12T14:04:13.000ZAspen and Africa CDC advance long-term Vaccine Supply Partnership for Africahttps://www.pharmaradar360.com/article/0647f31d72a14b92Pharma Surgeen2026-05-12T13:58:59.000ZFinding Genius podcast: AI enhanced enzymes & the future of sustainable manufacturinghttps://www.pharmaradar360.com/article/e634b41cae66c73aPharma Surgeen2026-05-12T12:48:53.000ZDecision: Medical devices given exceptional use authorisationshttps://www.pharmaradar360.com/article/312ca91fb5c2d2bbPharma Surgeen2026-05-12T12:46:01.000ZField Safety Notices: 4 to 8 May 2026https://www.pharmaradar360.com/article/3a95110493cc83fePharma Surgeen2026-05-12T12:18:47.000ZACRP Fellow Highlights Ongoing Efforts in the Professionalization of Clinical Researchhttps://www.pharmaradar360.com/article/ca7c212e4017198bPharma Surgeen2026-05-12T10:45:00.000ZMerck Highlights New Long-Term Data and Advancements Across Broad Oncology Portfolio and Pipeline Research at ASCO 2026https://www.pharmaradar360.com/article/9a1e9035fcd760e9Pharma Surgeen2026-05-12T07:24:22.000ZLa AEMPS informa de posibles daños en los generadores de impulso implantables de los sistemas de neuroestimulación Infinity y Proclaimhttps://www.pharmaradar360.com/article/181f15846c84014fPharma Surgeen2026-05-12T05:24:41.000ZRoche receives CE mark for new blood test to detect Alzheimer's pathology: Elecsys® plasma phosphorylated-tau 217 (pTau217)https://www.pharmaradar360.com/article/4c8e47af9419aec3Pharma Surgeen2026-05-12T04:00:00.000ZBristol Myers Squibb and Hengrui Pharma Announce Strategic Agreements to Advance Innovative Medicines Across Oncology, Hematology, and Immunologyhttps://www.pharmaradar360.com/article/ea16981f511e5cedPharma Surgeen2026-05-12T03:00:00.000Z[IBENTO][IBENTO]PMDA-ATC GMP Inspection Seminar 2026 applications openhttps://www.pharmaradar360.com/article/c1fc15e37057a98cPharma Surgeen2026-05-12T00:00:00.000ZWhat Some People Get Wrong about Cortisolhttps://www.pharmaradar360.com/article/0863fbe11690439dPharma Surgeen2026-05-12T00:00:00.000ZUnited Therapeutics Corporation to Present at the RBC Capital Markets Global Healthcare Conferencehttps://www.pharmaradar360.com/article/5135582693693dfaPharma Surgeen2026-05-12T00:00:00.000ZBausch Health to Participate in Barclays 30th Annual Leveraged Finance Conferencehttps://www.pharmaradar360.com/article/1536a63ba829dd38Pharma Surgeen2026-05-12T00:00:00.000ZSputum-Based Test May Identify Drug Targets in Asthma and COPD – Patient Care Onlinehttps://www.pharmaradar360.com/article/444ff6fb16df7109Pharma Surgeen2026-05-11T22:32:01.000ZUpdated EXOZ investor pitch by Chris Marlett